K-numberK250940
Device nameAtmo Gas Capsule System
ApplicantAtmo Biosciences, Ltd.
Product codeNYV
Device classClass II
Decision dateJun 26, 2025
DecisionSubstantially Equivalent
Regulation876.1725
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Atmo Gas Capsule System is an ingestible telemetric medical device that measures gastrointestinal transit times to evaluate motility disorders. It measures gastric emptying time (GET) for suspected gastroparesis and colonic transit time (CTT) for chronic constipation by using onboard sensors to detect temperature, hydrogen, carbon dioxide, oxygen levels, capsule tumble, and antenna reflectance as it passes through the GI tract.

Technological characteristics

The Atmo Capsule uses temperature, humidity, thermal conductivity, volatile organic compound, accelerometer, and antenna reflectometer sensors, compared to the predicate's temperature, pH, and pressure sensors. The Atmo operates at 433.9 MHz RF frequency versus the predicate's 434.2 MHz. The Atmo Capsule is smaller (27.8 mm × 11.1 mm, 3.8 g) and has longer battery life (>240 hours) than the predicate. Data flows from capsule to receiver to cloud portal, whereas the predicate uses local PC analysis. Both are single-use, non-sterile, and provide similar transit time measurements with automatic marker identification requiring manual confirmation.

Test standards cited

Not stated in this summary.

Substantial equivalence argument

The Atmo Gas Capsule System is substantially equivalent because it has the same intended use and indications as the SmartPill predicate—measuring GI transit times to evaluate motility disorders. Although the Atmo uses different sensors and algorithms, clinical testing in 213 participants showed Bland-Altman agreement between the two devices for GET and CTT with all pre-determined endpoints met. No serious adverse events were observed, and the safety/effectiveness profile matches the predicate. The minor differences in technological design (sensors, RF frequency, data transmission pathway) do not create new safety or effectiveness concerns and do not alter the diagnostic function.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →